CLAIMS

1. Use of a composition comprising mesenchymal lineage precursor or stem cells (MLPSCs) in the manufacture of a medicament for improving visual acuity in a human subject suffering from an ocular disease, in which the ocular disease is optic nerve inflammation, and in which the medicament comprises MLPSCs in an amount sufficient to improve visual acuity.

2. Use according to Claim 1, in which the ocular disease is also associated with degeneration of the optic nerve photoreceptors.

3. Use according to Claim 1 or 2, in which the subject has previously been treated with an anti-VEGF agent.

4. Use according to any preceding claim, in which the subject has reduced neovascularisation in the optic tissue.

5. Use according to Claim 3 or 4, in which the subject has been treated with:

a monthly dosage of anti-VEGF agent for at least 1 month, or at least 2 months, or at least 3 months; and/or

at least two doses of anti-VEGF agent.

6. Use according to any preceding claim, in which the agent is an anti-VEGF antibody.

7. Use according to any preceding claim, in which the mesenchymal lineage precursor or stem cells are isolated by immunoselection.

8. Use according to Claim 7, in which the immunoselected cells are culture expanded prior to administration.

9. Use according to any preceding claim, in which the mesenchymal lineage precursor or stem cells are culture expanded mesenchymal stem cells.

10. Use according to any of Claims 1 and 3 to 9, in which the medicament comprises a dose of MLPSCs comprising:

less than 350,000 cells, or less than 250,000 cells, or less than 100,000 cells, or less than 95,000 cells, or less than 90,000 cells or less than 80,000 cells, or less than 75,000 cells, or less than 70,000 cells;

less than 100,000 cells per mL of vitreous humor, or less than 75,000 cells per mL of vitreous humor, or less than 50,000 cells per mL of vitreous humor, or less than 25,000 cells per mL of vitreous humor, less than 20,000 cells per mL of vitreous humor; or

about 24,500 MPCs per mL of vitreous humor.

11. Use according to any preceding claim, in which the MLPSCs are formulated as a single dose.

12. Use according to any preceding claim, in which the MLPSCs are formulated for administration intravitreally.

13. Use according to any preceding claim, in which the medicament or composition comprises MLPSCs in an amount sufficient to result in at least a 10-point improvement from baseline in composite NEI VFQ-25 score over at least a 3 month period, or at least a 6 month period, or at least a 12 month period, or at least an 18 month period, or at least a 24 month period after administration to a subject.

14. Use according to any preceding claim, in which the medicament or composition comprises MLPSCs in an amount sufficient to result in a reduction in optical coherence tomograph (OCT) within a 3 month period after administration to a subject.